Atlas Trials

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Clinical trial NCT03820141 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03820141
Sponsor
The Methodist Hospital Research Institute
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2020-06-30
Primary completion
2024-10-30
Enrollment
51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.